肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
8期
526-528,531
,共4页
刘京龙%邓志华%郭素雅%张瑾
劉京龍%鄧誌華%郭素雅%張瑾
류경룡%산지화%곽소아%장근
肝肿瘤%基因疗法药物疗法,联合
肝腫瘤%基因療法藥物療法,聯閤
간종류%기인요법약물요법,연합
Liver neoplasms%Gene therapy%Drug therapy,combination
目的 研究腺病毒介导的Ad-hTERTp-单纯疱疹病毒胸苷激酶/丙氧鸟苷(Ad-hTERTp-HSV-TK/GCV)自杀基因系统联合奥沙利铂对人类肝癌细胞HepG2的体外杀伤作用.方法 将带有hTERT启动子驱动HSV-TK基因的重组复制缺陷型腺病毒Ad-hTERTp-HSV-TK作为载体.感染复数(MOI)为100转染HepG2细胞,观察不同浓度的Ad-hTERTp-HSV-TK/GCV、奥沙利铂及二者联合对HepG2细胞生长的影响.用锥虫蓝活细胞拒染法、四甲基偶氮唑盐比色(MTT)法检测各干预组肝癌细胞生长的抑制率.结果 3组HepG2细胞的生长均不同程度被抑制,且随药物浓度的增加抑制作用显著增强.Ad-hTERTp-HSV-TK/GCV联合奥沙利铂组抑制率最高(86.63%),与Ad-hTERTp-HSV-TK/GCV组抑制率(72.12%)及奥沙利铂组抑制率(59.41%)相比差异均有统计学意义(P<0.05).结论 Ad-hTERTp-HSV-TK/GCV联合奥沙利铂可显著增强对HepG2细胞的杀伤作用,增加靶向性的同时可以降低药物浓度,对临床用药有指导意义.
目的 研究腺病毒介導的Ad-hTERTp-單純皰疹病毒胸苷激酶/丙氧鳥苷(Ad-hTERTp-HSV-TK/GCV)自殺基因繫統聯閤奧沙利鉑對人類肝癌細胞HepG2的體外殺傷作用.方法 將帶有hTERT啟動子驅動HSV-TK基因的重組複製缺陷型腺病毒Ad-hTERTp-HSV-TK作為載體.感染複數(MOI)為100轉染HepG2細胞,觀察不同濃度的Ad-hTERTp-HSV-TK/GCV、奧沙利鉑及二者聯閤對HepG2細胞生長的影響.用錐蟲藍活細胞拒染法、四甲基偶氮唑鹽比色(MTT)法檢測各榦預組肝癌細胞生長的抑製率.結果 3組HepG2細胞的生長均不同程度被抑製,且隨藥物濃度的增加抑製作用顯著增彊.Ad-hTERTp-HSV-TK/GCV聯閤奧沙利鉑組抑製率最高(86.63%),與Ad-hTERTp-HSV-TK/GCV組抑製率(72.12%)及奧沙利鉑組抑製率(59.41%)相比差異均有統計學意義(P<0.05).結論 Ad-hTERTp-HSV-TK/GCV聯閤奧沙利鉑可顯著增彊對HepG2細胞的殺傷作用,增加靶嚮性的同時可以降低藥物濃度,對臨床用藥有指導意義.
목적 연구선병독개도적Ad-hTERTp-단순포진병독흉감격매/병양조감(Ad-hTERTp-HSV-TK/GCV)자살기인계통연합오사리박대인류간암세포HepG2적체외살상작용.방법 장대유hTERT계동자구동HSV-TK기인적중조복제결함형선병독Ad-hTERTp-HSV-TK작위재체.감염복수(MOI)위100전염HepG2세포,관찰불동농도적Ad-hTERTp-HSV-TK/GCV、오사리박급이자연합대HepG2세포생장적영향.용추충람활세포거염법、사갑기우담서염비색(MTT)법검측각간예조간암세포생장적억제솔.결과 3조HepG2세포적생장균불동정도피억제,차수약물농도적증가억제작용현저증강.Ad-hTERTp-HSV-TK/GCV연합오사리박조억제솔최고(86.63%),여Ad-hTERTp-HSV-TK/GCV조억제솔(72.12%)급오사리박조억제솔(59.41%)상비차이균유통계학의의(P<0.05).결론 Ad-hTERTp-HSV-TK/GCV연합오사리박가현저증강대HepG2세포적살상작용,증가파향성적동시가이강저약물농도,대림상용약유지도의의.
Objective To evaluate the lethal effect of adenovirus-mediated Ad-hTERTp-HSV-TK/GCV suicide gene system in combination with oxaliplatin (L-OHP) on human hepato carcinoma cell line HepG2 in vitro.Methods It was used that the replication-defective adenovirus carring the HSV-TK gene under control of the hTERT promoter to transfer the HepG2 cells in vitro. Human hepato carcinoma cell line HepG2 was transfected with MOI=100. It was studied that the grow inhibitory effct with Ad-hTERTp-HSV-TK/GCV therapy, oxaliplatin, Ad-hTERTp-HSV-TK/GCV therapy in combination with oxaliplatin through different drug concentration on human hepato carcinoma cell line HepG2. The growth inhibition rate of HepG2 cells was determined by trypan blue exclusion assay and MTT.Results The growth of HepG2 cells Ad-hTERTp-HSV-TK/GCV, oxaliplatin, and combination of Ad-hTERTp-HSV-TK/GCV and oxaliplatin was significantly slower.The more concentration the greater inhibition of cell growth. The growth inhibition rate of combined Ad-hTERTp-HSV-TK/GCV with oxaliplatin was 86.63 %.The growth inhibition rate of Ad-hTERTp-HSV-TK/GCV was 72.12 % compared to the combined therapy (P =0.023). The growth inhibition rate of oxaliplatin was 59.41% compared to the combined therapy (P =0.019). Combination of Ad-hTERTp-HSV-TK/GCV and oxaliplatin resulted in greater inhibition of cell growth compared with TK gene and L-OHP (P <0.05).Conclusion HSV-TK/GCV in combination with L-OHP can enhance thelethal effect of suicide gene therapy against HepG2 cells.It is more targetable than the function of single drug therapy.Also, it could reduce drug level and plays an important role on the future's clinical medication.